Trial Profile
A clinical study will investigate the tolerability of histamine H3 receptor antagonists [Evotec AG]. Histamine H3 receptor antagonists have been indicated for use in improving cognition, alertness and attention.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Histamine H3 receptor antagonists (Primary)
- Indications Cognition disorders; Narcolepsy
- Focus Adverse reactions
- 29 Apr 2010 New trial record